Bronchiectasis is a chronic lung condition defined by permanent, damaging airway enlargement.

Health · Published 30 September 2026 Swipe more like this →

In short: Bronchiectasis turns your lungs into a trap for bacteria and mucus. When airways become permanently dilated, they lose their ability to clear secretions, triggering a self-perpetuating cycle of inflammation and tissue destruction. While often linked to infections or genetic disorders, the condition remains a complex, life-altering respiratory challenge.

At its core, bronchiectasis is an obstructive lung disease characterized by the irreversible widening of the bronchi. This structural change is typically the result of an excessive inflammatory response following an initial injury, such as a severe respiratory infection, autoimmune destruction, or the aspiration of foreign objects. Once the airways are distorted, they struggle to clear mucus, which accumulates and creates an ideal environment for bacterial colonization. This colonization triggers further immune activity, specifically from neutrophils, which release elastases that damage the bronchial walls, fueling a vicious cycle of progressive lung architecture destruction.

The clinical presentation is often marked by a chronic, productive cough, shortness of breath, and chest pain. Diagnosis is typically confirmed through computed tomography, which reveals the extent of airway dilation and wall thickening. While cystic fibrosis is a major driver of the disease, accounting for up to half of cases, many patients have non-CF bronchiectasis. In these instances, causes can range from primary ciliary dyskinesia and alpha-1 antitrypsin deficiency to systemic autoimmune conditions like rheumatoid arthritis or Sjögren syndrome. Notably, recent diagnostic advancements have reduced the proportion of idiopathic cases, identifying an underlying etiology in 60–90% of patients.

Management focuses on interrupting this cycle of infection and inflammation. Standard care includes airway clearance techniques to mobilize secretions and targeted antibiotic therapy to manage bacterial burdens. While surgery is sometimes used for localized disease or to remove obstructions, it lacks large-scale randomized trial validation. Emerging pharmacological interventions, such as brensocatib—approved in the United States in August 2025—aim to reduce exacerbation rates. Because the condition is progressive, clinical tools like the Bronchiectasis Severity Index and the FACED scale are used to predict outcomes based on factors like lung function, age, and body mass index, helping clinicians tailor treatment to the individual's specific risk profile.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• When your lungs lose the ability to clear their own debris
• Pulmonary fibrosis: When the lungs lose their ability to breathe
• The permanent architecture of breath: understanding chronic obstructive pulmonary disease
• The progressive scarring of the lungs that steals breath from the body
• The complex biological puzzle of chronic airway inflammation
• A bruise is bleeding you can see without breaking the skin
• Breast milk changes its recipe during a single feed, and between day and night
• Is your jaw clenching a subconscious habit or a mysterious involuntary neurological reflex?
• Most breast cancers are found before symptoms appear
• Can a complex opioid derivative help solve the crisis of addiction and overdose?
• Metastases outnumber primary brain tumors four to one
• The antidepressant that behaves differently from most others, including helping smokers quit

More in Health, medicine and disease · More in Health · Latest · A–Z · All topics